Correspondence |

Lentiginous Eruption Due to Topical Immunotherapy

Antonella Tosti, MD; Bianca Maria Piraccini, MD; Cosimo Misciali, MD; Colombina Vincenzi, MD
Arch Dermatol. 2003;139(4):544-545. doi:10.1001/archderm.139.4.544.
Text Size: A A A
Published online


Topical immunotherapy is universally used for the treatment of alopecia areata. The purpose of the treatment is to induce a mild contact dermatitis that may induce hair regrowth by mechanisms still unknown. Suggested mechanisms include antigenic competition, nonspecific systemic suppression of delayed-type hypersensitivity reactions, and interference with proinflammatory cytokine activity.

Chemicals currently used for topical immunotherapy are squaric acid dibutylester and diphencyprone. Topical immunotherapy is usually well tolerated, and adverse effects, including eczematous reactions, facial and scalp edema, neck lymphadenopathy, contact urticaria, vitiligo, pompholyxlike eruption, erythema multiforme, and postinflammatory hyperpigmentation or hypopigmentation,1 are mild and reversible. Pigmentation of the treated area is commonly observed (up to 12.2% of cases),2 especially in patients with dark skin. We describe a previously unreported adverse effect of topical immunotherapy: the development of widespread lentigines.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours


Place holder to copy figure label and caption
Figure 1.

Lentiginous eruption and contact dermatitis along the occipital hairline.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Pathological features showing a lentigo with melanocyte atypia.

Graphic Jump Location




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles